þ | ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
o | TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
3
INCOME |
||||
Contribution Company Matching (co. stock) |
$ | 274,057 | ||
Contribution Participant 401(k) |
532,134 | |||
Investment Earnings |
72,696 | |||
Cash Value of Surrendered Insurance |
0 | |||
Realized Gain From Asset Sale |
0 | |||
Insurance Premium Refunds |
0 | |||
Other Income Rollovers |
21,703 | |||
Unrealized Depreciation of Assets |
(648,963 | ) | ||
Total Income |
$ | 251,627 | ||
EXPENSES |
||||
Life Insurance Premiums Paid |
$ | 0 | ||
Payments to Participants |
122,928 | |||
Bank Charges |
0 | |||
Brokerage Fees |
0 | |||
Administration Expenses Paid By the Trust |
0 | |||
Other Miscellaneous Expenses |
||||
Total Expenses |
$ | 122,928 | ||
Income Over Expenses |
$ | 128,699 | ||
Assets At The Beginning Of The Plan Year |
1,653,810 | |||
Assets At The End Of The Plan Year |
$ | 1,782,509 | ||
As of | As of | |||||||
January 1, | December 31, | |||||||
2008 | 2008 | |||||||
ASSETS |
||||||||
Cash (Interest Bearing) |
$ | 226,798 | $ | 493,871 | ||||
Contribution Receivable (Co. Match) |
0 | 0 | ||||||
Contribution Receivable (401-K) |
0 | 0 | ||||||
Government Securities |
0 | 0 | ||||||
Mutual Funds |
1,141,842 | 883,904 | ||||||
Corporate Stocks & Bonds (Employer Stock) |
218,411 | 346,980 | ||||||
Real Estate and Mortgages |
0 | 0 | ||||||
Depreciable Buildings/Property |
0 | 0 | ||||||
Participant Loans |
66,759 | 57,754 | ||||||
Other Assets |
0 | 0 | ||||||
Total Assets |
$ | 1,653,810 | $ | 1,782,509 | ||||
LIABILITIES |
||||||||
Payables |
0 | 0 | ||||||
Acquisition Indebtedness |
0 | 0 | ||||||
Other Liabilities |
0 | 0 | ||||||
Total Liabilities |
$ | 0 | $ | 0 | ||||
NET ASSETS (Assets Less Liabilities) |
$ | 1,653,810 | $ | 1,782,509 | ||||
4
SPECTRUM PHARMACEUTICALS, INC. 401(K) PLAN |
||||
By: | Spectrum Pharmaceuticals, Inc. | |||
By: | /s/ Shyam Kumaria | |||
Shyam Kumaria | ||||
Vice President, Finance |
5